Uppsala, Sweden, 2012-08-23 16:04 CEST (GLOBE NEWSWIRE) --
The Oasmia Annual Report for the fiscal year 2011/2012 is now available at the company website www.oasmia.com.
The Corporate Governance report for the fiscal year 2011/2012 is also available at the company website www.oasmia.com
About Oasmia Pharmaceutical AB
Oasmia Pharmaceutical AB develops a new generation of drugs within human and veterinary oncology. The product development aims to manufacture novel formulations based on well-established cytostatics which, in comparison with current alternatives, show improved properties, a reduced side-effect profile and an expanded therapeutic area. The product development is based on in-house research within nanotechnology and company patents. The company share is listed on NASDAQ OMX Stockholm and the Frankfurt Stock Exchange.
“Oasmia is required under the Financial Instruments Trading Act to make the information in this press release public. The information was submitted for publication at 4 p.m. CET on August 23.”
Maria Lundén, Head of Public Relations, Oasmia Pharmaceutical AB. E-mail: press@oasmia.com Phone: +46 (0) 18 50 54 40.
